News Sentiment

TRVI sentiment intelligence

Trevi Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.07 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+6.9% over one week, +10.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 6.9% Price confirming higher
Trend fit Trend active 10.8% over four weeks
Fair value 207.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
MarketBeat 9
Market source 9
TradingView 7
simplywall.st 5
Investing.com 4
MT Newswires 3
timothysykes.com 3
www.marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 21
Analyst action 6
Balance sheet 6
Guidance 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
marketscreener.com Direct company coverage

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target

BMO Capital has initiated coverage on Trevi Therapeutics (TRVI) with an Outperform rating and set a price target of $36. This announcement follows B. Riley's recent adjustment of Trevi Therapeutics' price target to $31 from $21, maintaining a Buy rating. Trevi Therapeutics is a c

Tone
Positive 74/100
Event
Analyst action
Published
21 Jul 2026 11:12
Source
marketscreener.com
MarketBeat Direct company coverage

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why

Trevi Therapeutics (NASDAQ:TRVI) saw its shares drop 5.1% on Monday, trading as low as $18.03 with below-average volume, following a previous close of $19.07. This decline occurred despite several analysts recently raising price targets and maintaining a "Moderate Buy" consensus

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 18:09
Source
MarketBeat
MarketBeat Direct company coverage

HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

HC Wainwright has raised its price target for Trevi Therapeutics (NASDAQ:TRVI) to $24 from $21, maintaining a buy rating and suggesting a potential upside of 25.85%. Despite a recent quarterly EPS miss, other analysts also hold a generally positive outlook, contributing to a cons

Tone
Positive 67/100
Event
Guidance
Published
20 Jul 2026 11:41
Source
MarketBeat
www.timothysykes.com Direct company coverage

_TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum

Trevi Therapeutics Inc. (TRVI) stock surged over 11% following optimistic investor response to clinical progress and a non-deal roadshow. Despite being a development-stage biotech with negative profitability and cash burn, the company boasts a strong balance sheet with substantia

Tone
Positive 75/100
Event
Balance sheet
Published
19 Jul 2026 14:07
Source
www.timothysykes.com
timothysykes.com Direct company coverage

TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers

Trevi Therapeutics (TRVI) stock surged by 11.6% due to strong investor optimism driven by promising clinical progress and aggressive accumulation by traders. Despite being a clinical-stage biotech with no product revenue and negative fundamentals, TRVI boasts exceptional liquidit

Tone
Positive 80/100
Event
Earnings
Published
19 Jul 2026 10:08
Source
timothysykes.com
timothysykes.com Direct company coverage

Trevi Therapeutics Stock Jumps As Momentum Traders Pile In

Trevi Therapeutics Inc. (TRVI) stock has experienced an 11.6% jump, driven by positive drug trial news and aggressive buying interest from momentum traders. Despite being a clinical-stage biotech with negative profitability, the company maintains strong liquidity with $172M in ca

Tone
Positive 73/100
Event
Balance sheet
Published
18 Jul 2026 15:09
Source
timothysykes.com
StocksToTrade Direct company coverage

TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest

Trevi Therapeutics (TRVI) stock experienced an 11.6% surge following promising clinical data, generating significant investor and trading interest. The company is set to meet institutional investors in London, contributing to positive sentiment. Despite being a clinical-stage bio

Tone
Positive 81/100
Event
Market update
Published
18 Jul 2026 11:38
Source
StocksToTrade
timothysykes.com Direct company coverage

TRVI Jumps As Trevi Therapeutics Extends Bullish Run

Trevi Therapeutics Inc. (TRVI) stock has jumped by 11.6% due to optimism over its latest clinical trial developments and a Cantor Fitzgerald-hosted non-deal roadshow in London. Despite strong liquidity and no debt, the company is pre-revenue with negative returns and significant

Tone
Positive 74/100
Event
Balance sheet
Published
18 Jul 2026 10:08
Source
timothysykes.com
Market source Direct company coverage

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

Trevi Therapeutics (TRVI) saw its share prices rise by 9.85% after its CEO and Chief Development Officer presented strong clinical trial results for Haduvio, their treatment candidate for chronic cough, at a European conference. Haduvio, an extended-release formulation of nalbuph

Tone
Positive 80/100
Event
Earnings
Published
17 Jul 2026 19:20
Source
Market source
StocksToTrade Direct company coverage

TRVI Stock Firms Up As Haduvio Story Hits Center Stage

Trevi Therapeutics Inc. (TRVI) stock is showing a strong upturn, driven by optimism surrounding its Haduvio clinical development and an aggressive outreach campaign. Management is engaging in a London non-deal roadshow hosted by Cantor Fitzgerald and participating in multiple ind

Tone
Positive 74/100
Event
Market update
Published
17 Jul 2026 17:40
Source
StocksToTrade
MarketBeat Direct company coverage

Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?

Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in trading volume and stock price, with shares jumping to $20.12 on Friday. Analysts maintain a generally positive outlook, reiterating "buy" ratings and setting an average price target of $22.67, despite the compan

Tone
Positive 66/100
Event
Guidance
Published
17 Jul 2026 16:40
Source
MarketBeat
MarketBeat Direct company coverage

Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in call option trading, with 13,996 call options bought on Wednesday, a 1,258% increase from the typical volume. This occurred despite a 0.43% share price drop to $17.48. Analysts maintain a "Buy" consensus rating w

Tone
Neutral 50/100
Event
Analyst action
Published
15 Jul 2026 17:48
Source
MarketBeat
MarketBeat Direct company coverage

Candriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVI

Candriam S.C.A. acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the first quarter, purchasing 773,620 shares valued at approximately $9.23 million. This investment represents about 0.60% of Trevi Therapeutics' total ownership. Other institutional investor

Tone
Positive 71/100
Event
Earnings
Published
13 Jul 2026 08:11
Source
MarketBeat
MarketBeat Direct company coverage

SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI

SG Americas Securities LLC significantly reduced its stake in Trevi Therapeutics (NASDAQ:TRVI) by 77.5% in the first quarter, selling 96,511 shares and leaving them with 28,051 shares. Despite this reduction, institutional investors collectively hold a strong position, with 95.76

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 09:09
Source
MarketBeat
Ad-hoc-news.de Direct company coverage

TRVi stock stays tied to Trevi Therapeutics' clinical outlook

Trevi Therapeutics (TRVI) stock performance is predominantly influenced by its clinical pipeline progress, especially its oral therapies for chronic cough and fibrosis-related conditions. The company's valuation relies heavily on successful study readouts and its ability to trans

Tone
Neutral 50/100
Event
Guidance
Published
09 Jul 2026 18:17
Source
Ad-hoc-news.de
TradingView Direct company coverage

Price to earnings forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI

This article displays information regarding the forward price-to-earnings ratio for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data point within a trading platform interface for investors and analysts, without providing further analysis or discussion. The a

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 23:41
Source
TradingView
Investing.com Direct company coverage

Trevi Therapeutics stock hits all-time high at 19.33 USD

Trevi Therapeutics (TRVI) stock recently reached an all-time high of $19.33, reflecting a significant 226.05% increase over the past year and strong investor confidence. The company reported a robust cash position and is advancing its clinical programs, including the pivotal prog

Tone
Positive 75/100
Event
Balance sheet
Published
08 Jul 2026 10:09
Source
Investing.com
TradingView Direct company coverage

Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI

This page from TradingView provides financial information for Trevi Therapeutics, Inc. (NASDAQ: TRVI), specifically focusing on its price to sales forward metric. The content indicates the market status (closed) and the availability of various financial tools and data for the com

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 09:10
Source
TradingView